Estimating Real-World Persistency and Compliance

The Challenge

A pharmaceutical company needed to forecast the launch of an upcoming oncology drug but faced the challenge of relying on clinical trial data for persistency and compliance metrics, which often did not reflect real-world scenarios.

ProcDNA's Solution

Data Collection and Analysis

Collected 12 months of patient claims data and assessed the gap between consecutive claims, comparing it to a threshold (grace period) to determine persistency.

Persistency and Compliance Estimation

Calculated persistency as the percentage of patients continuing therapy after a specific period, while compliance was measured by tracking the percentage of days a patient adhered to their prescribed dosage.

Impact